Evidence map›Paper›PMID 38258464›Full record

ArticleEpidemiology and infection2024

Seroprevalence of severe acute respiratory syndrome coronavirus 2 N antibodies between December 2021 and march 2023 in Japan.

Seiya Yamayoshi, Etsuko Nagai, Keiko Mitamura, Masao Hagihara, Ryo Kobayashi, Satoshi Takahashi, Akimichi Shibata, Yoshifumi Uwamino, Naoki Hasegawa, Asef Iqbal and 4 more

Abstract read
In one paragraph

Article in Epidemiology and infection, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Seiya YamayoshiDivision of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.ORCID 0000-0001-7768-5157
Etsuko NagaiDepartment of Laboratory Medicine, Research Hospital, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Keiko MitamuraDivision of Infection Control, Eiju General Hospital, Tokyo, Japan.
Masao HagiharaDepartment of Hematology, Eiju General Hospital, Tokyo, Japan.
Ryo KobayashiDivision of Laboratory Medicine, Sapporo Medical University Hospital, Sapporo, Japan.
Satoshi TakahashiDepartment of Infection Control and Laboratory Medicine, Sapporo Medical University, Sapporo, Japan.
Akimichi ShibataDepartment of Pediatrics, Japanese Red Cross Ashikaga Hospital, Tochigi, Japan.
Yoshifumi UwaminoDepartment of Laboratory Medicine, School of Medicine, Keio University, Tokyo, Japan.
Naoki HasegawaDepartment of Infectious Diseases, School of Medicine, Keio University, Tokyo, Japan.
Asef IqbalDepartment of Pediatrics, NHO Saitama Hospital, Saitama, Japan.
Isamu KamimakiDepartment of Pediatrics, NHO Saitama Hospital, Saitama, Japan.
Kiyoko Iwatsuki-HorimotoDivision of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Tokiko Nagamura-InoueDepartment of Laboratory Medicine, Research Hospital, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Yoshihiro KawaokaDivision of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.

Funding

NIAID NIH HHS HHSN272201400008C
6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in 2019 in China and rapidly spread worldwide, leading to a pandemic. The threat of SARS-CoV-2 is subsiding as most people have acquired sufficient antibodies through vaccination and/or infection to prevent severe COVID-19. After the emergence of the omicron variants, the seroprevalence of antibodies against the N protein elicited by SARS-CoV-2 infection ranged from 44.4% to 80.2% in countries other than Japan. Here, we assessed the seroprevalence in Japan before and after the appearance of omicron variants. Serosurveillance of antibodies against N was conducted between December 2021 and March 2023 in Japan. In total, 7604 and 3354 residual serum or plasma samples were collected in the Tokyo metropolitan area and Sapporo, respectively. We found that the seroprevalence in representative regions of Japan increased approximately 3% to 23% after the emergence of the omicron variants. We also found higher seroprevalence among the young compared with the elderly. Our findings indicate that unlike other countries, most of the Japanese population has not been infected, raising the possibility of future SARS-CoV-2 epidemics in Japan.

Indexed as

COVID-19SARS-CoV-2AgedAntibodies, ViralHumansJapanPandemicsSeroepidemiologic StudiesAntibodies, ViralCOVID-19JapanN proteinSARS-CoV-2seroprevalence

Identifiers

PMID38258464
PMCPMC10894890

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.